AstraZeneca Pharma India Share Price
Start SIP in AstraZeneca Pharma India
Start SIPAstraZeneca Pharma India Performance
Day Range
- Low 6,722
- High 6,832
52 Week Range
- Low 4,311
- High 7,572
- Open Price6,722
- Previous Close6,800
- Volume5166
Astrazeneca Pharma India Investment Rating
-
Master Rating:
-
Astrazeneca Pharma India has an operating revenue of Rs. 1,387.58 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 17% is great, ROE of 22% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 14% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 57 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 56 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 388 | 383 | 306 | 311 | 295 | 285 |
| Operating Expenses Qtr Cr | 349 | 334 | 291 | 258 | 228 | 225 |
| Operating Profit Qtr Cr | 38 | 49 | 15 | 53 | 67 | 60 |
| Depreciation Qtr Cr | 4 | 4 | 4 | 4 | 4 | 4 |
| Interest Qtr Cr | 0 | 0 | 1 | 1 | 0 | 0 |
| Tax Qtr Cr | -3 | 15 | 5 | 21 | 18 | 6 |
| Net Profit Qtr Cr | -12 | 39 | 16 | 52 | 54 | 17 |
AstraZeneca Pharma India Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 6
- Bearish Moving Average
- ___
- 10
- 20 Day
- ₹6,795.84
- 50 Day
- ₹6,691.58
- 100 Day
- ₹6,420.14
- 200 Day
- ₹5,920.96
- 20 Day
- ₹6,781.87
- 50 Day
- ₹6,787.21
- 100 Day
- ₹6,373.71
- 200 Day
- ₹5,926.99
AstraZeneca Pharma India Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 6,812.45 |
| Second Resistance | 6,877.55 |
| Third Resistance | 6,922.75 |
| RSI | 48.30 |
| MFI | 79.07 |
| MACD Single Line | 28.77 |
| MACD | 25.13 |
| Support | |
|---|---|
| First Support | 6,702.15 |
| Second Support | 6,656.95 |
| Third Supoort | 6,591.85 |
AstraZeneca Pharma India Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 5,504 | 223,793 | 40.66 |
| Week | 14,975 | 439,223 | 29.33 |
| 1 Month | 14,782 | 442,867 | 29.96 |
| 6 Month | 27,905 | 864,788 | 30.99 |
AstraZeneca Pharma India Result Highlights
AstraZeneca Pharma India Synopsis
NSE-Medical-Diversified
Astrazeneca Pharma I is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1295.53 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2024. AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563.| Market Cap | 16,868 |
| Sales | 1,388 |
| Shares in Float | 0.63 |
| No of funds | 126 |
| Yield | 0.36 |
| Book Value | 23.69 |
| U/D Vol ratio | 1.8 |
| LTDebt / Equity | |
| Alpha | 0.09 |
| Beta | 0.86 |
AstraZeneca Pharma India Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
|---|---|---|---|---|
| Promoters | 75% | 75% | 75% | 75% |
| Mutual Funds | 4.97% | 3.75% | 2.75% | 2.42% |
| Insurance Companies | ||||
| Foreign Portfolio Investors | 2.79% | 2.73% | 2.66% | 2.69% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 15% | 16.34% | 17.09% | 17.44% |
| Others | 2.24% | 2.18% | 2.5% | 2.45% |
AstraZeneca Pharma India Management
| Name | Designation |
|---|---|
| Mr. Narayan K Seshadri | Chairperson & Independent Director |
| Mr. Sanjeev Kumar Panchal | Executive Director |
| Ms. Bhavana Agrawal | Executive Director |
| Ms. Sylvia Lorena Varela Ramon | Non Executive Director |
| Ms. Hooi Bien Chuah | Non Executive Director |
| Ms. Shilpa Divekar Nirula | Independent Director |
| Ms. Revathy Ashok | Independent Director |
AstraZeneca Pharma India Forecast
Price Estimates
AstraZeneca Pharma India Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-08 | Quarterly Results | |
| 2024-05-27 | Audited Results & Dividend | |
| 2024-02-08 | Quarterly Results | |
| 2023-11-09 | Quarterly Results | |
| 2023-08-14 | Quarterly Results |
| Date | Purpose | Remarks |
|---|---|---|
| 2024-07-05 | FINAL | Rs.24.00 per share(1200%)Dividend |
| 2023-07-14 | FINAL | Rs.16.00 per share(800%)Dividend |
| 2022-07-08 | FINAL | Rs.8.00 per share(400%)Final Dividend |
| 2021-08-20 | INTERIM | Rs.2.00 per share(100%)Interim Dividend |
AstraZeneca Pharma India FAQs
What is Share Price of AstraZeneca Pharma India ?
AstraZeneca Pharma India share price is ₹6,747 As on 17 September, 2024 | 04:22
What is the Market Cap of AstraZeneca Pharma India ?
The Market Cap of AstraZeneca Pharma India is ₹16868.4 Cr As on 17 September, 2024 | 04:22
What is the P/E ratio of AstraZeneca Pharma India ?
The P/E ratio of AstraZeneca Pharma India is 176 As on 17 September, 2024 | 04:22
What is the PB ratio of AstraZeneca Pharma India ?
The PB ratio of AstraZeneca Pharma India is 23.7 As on 17 September, 2024 | 04:22